These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 39192724)

  • 1. Hepatitis C treatment outcome among people in prison: The SToP-C study.
    Ryan H; Dore GJ; Grebely J; Byrne M; Cunningham EB; Martinello M; Lloyd AR; Hajarizadeh B
    Liver Int; 2024 Nov; 44(11):2996-3007. PubMed ID: 39192724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
    Hajarizadeh B; Grebely J; Byrne M; Marks P; Amin J; McManus H; Butler T; Cunningham EB; Vickerman P; Martin NK; McHutchison JG; Brainard DM; Treloar C; Chambers GM; Grant L; Mcgrath C; Lloyd AR; Dore GJ;
    Lancet Gastroenterol Hepatol; 2021 Jul; 6(7):533-546. PubMed ID: 33965006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brief Report: HCV Universal Test-and-Treat With Direct Acting Antivirals for Prisoners With or Without HIV: A Prison Health Care Workers-Led Model for HCV Microelimination in Thailand.
    Supanan R; Han WM; Harnpariphan W; Ueaphongsukkit T; Ubolyam S; Sophonphan J; Tangkijvanich P; Thanprasertsuk S; Avihingsanon A;
    J Acquir Immune Defic Syndr; 2021 Dec; 88(5):465-469. PubMed ID: 34757974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
    Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH; Marks P; Quiene S; Siriragavan S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Dillon JF; Read P; Gane E; Dore GJ;
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):153-161. PubMed ID: 29310928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
    Tada T; Kurosaki M; Nakamura S; Hasebe C; Kojima Y; Furuta K; Kobashi H; Kimura H; Ogawa C; Yagisawa H; Uchida Y; Joko K; Akahane T; Arai H; Marusawa H; Narita R; Ide Y; Sato T; Kusakabe A; Tsuji K; Mori N; Kondo M; Mitsuda A; Izumi N
    J Med Virol; 2021 Nov; 93(11):6247-6256. PubMed ID: 34170517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
    Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
    J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Alaska Native/American Indian experience of hepatitis C treatment with sofosbuvir-based direct-acting antivirals.
    Townshend-Bulson L; Roik E; Barbour Y; Bruden DJT; Homan CE; Espera HGF; Stevenson TJ; Hewitt AM; Rhodes W; Gove JE; Plotnik JN; Snowball MM; McGilvray J; Simons BC; Johnston JM; McMahon BJ
    PLoS One; 2021; 16(12):e0260970. PubMed ID: 34855920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
    Jacobson IM; Lawitz E; Gane EJ; Willems BE; Ruane PJ; Nahass RG; Borgia SM; Shafran SD; Workowski KA; Pearlman B; Hyland RH; Stamm LM; Svarovskaia E; Dvory-Sobol H; Zhu Y; Subramanian GM; Brainard DM; McHutchison JG; Bräu N; Berg T; Agarwal K; Bhandari BR; Davis M; Feld JJ; Dore GJ; Stedman CAM; Thompson AJ; Asselah T; Roberts SK; Foster GR
    Gastroenterology; 2017 Jul; 153(1):113-122. PubMed ID: 28390869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus diversity and treatment outcomes in Benin: a prospective cohort study.
    Ahovègbé L; Shah R; Kpossou AR; Davis C; Niebel M; Filipe A; Goldstein E; Alassan KS; Keke R; Sehonou J; Kodjoh N; Gbedo SE; Ray S; Wilkie C; Vattipally S; Tong L; Kamba PF; Gbenoudon SJ; Gunson R; Ogwang P; Thomson EC
    Lancet Microbe; 2024 Jul; 5(7):697-706. PubMed ID: 38889738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial.
    Wei L; Lim SG; Xie Q; Văn KN; Piratvisuth T; Huang Y; Wu S; Xu M; Tang H; Cheng J; Le Manh H; Gao Y; Mou Z; Sobhonslidsuk A; Dou X; Thongsawat S; Nan Y; Tan CK; Ning Q; Tee HP; Mao Y; Stamm LM; Lu S; Dvory-Sobol H; Mo H; Brainard DM; Yang YF; Dao L; Wang GQ; Tanwandee T; Hu P; Tangkijvanich P; Zhang L; Gao ZL; Lin F; Le TTP; Shang J; Gong G; Li J; Su M; Duan Z; Mohamed R; Hou JL; Jia J
    Lancet Gastroenterol Hepatol; 2019 Feb; 4(2):127-134. PubMed ID: 30555048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 'one-stop-shop' point-of-care hepatitis C RNA testing intervention to enhance treatment uptake in a reception prison: The PIVOT study.
    Sheehan Y; Cunningham EB; Cochrane A; Byrne M; Brown T; McGrath C; Lafferty L; Tedla N; Dore GJ; Lloyd AR; Grebely J
    J Hepatol; 2023 Sep; 79(3):635-644. PubMed ID: 37116714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-duration treatment with the novel non-nucleoside inhibitor CDI-31244 plus sofosbuvir/velpatasvir for chronic hepatitis C: An open-label study.
    Chua JV; Ntem-Mensah A; Abutaleb A; Husson J; Mutumbi L; Lam KW; Ghosh A; Romani S; Poonia B; Lee S; Luz Pascual M; Frumkin LR; Kottilil S
    J Med Virol; 2021 Jun; 93(6):3752-3760. PubMed ID: 33150966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
    Wilson E; Covert E; Hoffmann J; Comstock E; Emmanuel B; Tang L; Husson J; Chua J; Price A; Mathur P; Rosenthal E; Kattakuzhy S; Masur H; Kottilil S
    J Hepatol; 2019 Sep; 71(3):498-504. PubMed ID: 31173815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Continuum of hepatitis C care cascade in prison and following release in the direct-acting antivirals era.
    Hariri S; Sharafi H; Sheikh M; Merat S; Hashemi F; Azimian F; Tamadoni B; Ramazani R; Gouya MM; Abbasi B; Tashakorian M; Alasvand R; Alavian SM; Poustchi H; Malekzadeh R
    Harm Reduct J; 2020 Oct; 17(1):80. PubMed ID: 33081794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of Hepatitis C Virus Infection and Efficacy of Sofosbuvir-Velpatasvir and Sofosbuvir-Daclatasvir Treatment Regimens in End-stage Renal Disease Patients on Maintenance Hemodialysis.
    Bhat MA; Mir AN; Parry MA; Parray IA
    Saudi J Kidney Dis Transpl; 2023 Nov; 34(6):570-575. PubMed ID: 38725207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.
    Matthews GV; Bhagani S; Van der Valk M; Rockstroh J; Feld JJ; Rauch A; Thurnheer C; Bruneau J; Kim A; Hellard M; Shaw D; Gane E; Nelson M; Ingiliz P; Applegate TL; Grebely J; Marks P; Martinello M; Petoumenos K; Dore GJ; ; ; ;
    J Hepatol; 2021 Oct; 75(4):829-839. PubMed ID: 34023350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.
    Bourlière M; Gordon SC; Schiff ER; Tran TT; Ravendhran N; Landis CS; Hyland RH; Stamm LM; Zhang J; Dvory-Sobol H; Subramanian GM; Brainard DM; McHutchison JG; Serfaty L; Thompson AJ; Sepe TE; Curry MP; Reddy KR; Manns MP
    Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):559-565. PubMed ID: 29859740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons.
    Lim AG; Stone J; Hajarizadeh B; Byrne M; Chambers GM; Martin NK; Grebely J; Dore GJ; Lloyd AR; Vickerman P
    Hepatology; 2021 Nov; 74(5):2366-2379. PubMed ID: 34105797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world effectiveness of sofosbuvir/velpatasvir/voxilaprevir in 573 direct-acting antiviral experienced hepatitis C patients.
    Belperio PS; Shahoumian TA; Loomis TP; Backus LI
    J Viral Hepat; 2019 Aug; 26(8):980-990. PubMed ID: 31012179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
    Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S;
    J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.